fibronectin adhesion promoting peptide tfa

Fibronectin Adhesion-promoting Peptide (Heparin Binding Peptide) is an amino acid sequence in the carboxy-terminal heparin-binding domain of fibronectin that facilitates the assembly of mesenchymal stem cell (MSC) spheroids into larger aggregates.

PKG inhibitor peptide TFA (82801-73-8 free base) is an inhibitor of ATP-competitive cGMP-dependent protein kinase (PKG).

3X FLAG peptide TFA (402750-12-3 free base) (3X FLAG peptide TFA) is a synthetic peptide of 23 amino acid residue. The Asp-Tyr-Lys-Xaa-Xaa-Asp motif is repeated three times in the peptide.

Gastrin-Releasing Peptide, human(TFA) is a regulatory human peptide that elicits gastrin release and regulates gastric acid secretion and enteric motor function. The post-ganglionic fibers of the vagus nerve that innervate the G cells of the stomach release GRP, which stimulates the G cells to release gastrin.

RNAIII-inhibiting peptide TFA (RNAIII-inhibiting peptide(TFA))(228544-21-6 free base) inhibits S. aureus, effective in the diseases such as cellulitis, keratitis, septic arthritis, osteomylitis and mastitis.

CS1 peptide is present within type III homology connecting segment (IIICS) as well as C-274 (cell-binding domain). Fibronectin CS1 Peptide lacks the Arg-Gly-Asp-containing domain, actively inhibits tumor metastases in spontaneous and experimental metastas

C-MYC PEPTIDE EPITOPE TFA, the product of the c-myc proto-oncogene, is a helix-loop-helix leucine zipper phosphoprotein that regulates gene transcription in cell proliferation, cell differentiation and apoptosis. This peptide is a human c-myc epitope.

Antennapedia Peptide TFA (188842-14-0 free base), a peptide of 16 amino acids, is a member of the family of Cell-penetrating peptides, originally derived from the 60 amino acid long homeodomain of the Drosophila transcription factor Antennapedia.

Fibronectin Adhesion-promoting Peptide acetate (Heparin Binding Peptide acetate) is one of the heparin-binding amino acid sequences found in the carboxy-terminal heparin-binding domain of fibronectin.

Gastric inhibitory peptide 1 (GIP-1) (3-42), a fragment of the incretin hormone GIP and antagonist to the GIP receptor, is generated through the action of serum dipeptidyl peptidase 4 (DDP-4). When administered at 25 nmol/kg to an ob/ob mouse diabetes model, GIP-1 (3-42) elevates plasma glucose levels and lowers plasma insulin levels, demonstrating its effect on reducing insulin secretion from BRIN-BD11 pancreatic cells at a concentration of 100 nM.

Transdermal Peptide TFA (TD 1 Peptide TFA) is an 11-amino acid polypeptide that binds to Na+/K+ -atpase beta-subunit (ATP1B1) and interacts with the C terminal of ATP1B1.Transdermal Peptide TFA can enhance the transmission of some large molecules in the s

CCP Peptide TFA, a synthetic cyclic citrullinated peptide, serves as a serological substrate for the detection of anti-CCP antibodies and is a highly specific target for autoantibodies associated with rheumatoid arthritis (RA) [1] [2].

Tat-peptide 168-189, a cell-permeable, Tat-labeled fusion peptide derived from residues 168-189 of rat G3BP1, features the HIV Tat sequence at its least conserved terminus to enhance cellular uptake. It serves as the negative control for Tat-peptide 168-189 TFA, which promotes axon growth and neurite proliferation [1].

Tat-peptide 190-208 TFA is a Tat-labeled, cell-permeable fusion peptide derived from residues 190-208 of rat G3BP1. The HIV-derived Tat sequence at the peptide's least conserved region confers cellular permeability. This compound promotes axon growth and enhances neurite formation per neuron, suggesting an axon intrinsic mechanism of action. Additionally, it has potential applications in providing ischemic protection during endovascular repair of intracranial aneurysms [1].

(Leu31,Pro34)-Peptide YY (human) (TFA) is the trifluoroacetic acid (TFA) form of (Leu31,Pro34)-Peptide YY (human), a derivative of Peptide YY that acts as a potent and selective Y1 agonist, exhibiting a dissociation constant (K D) of 1.0 nM [1].

Autocamtide-2-related inhibitory peptide (TFA) is a highly specific and potent CaMKII inhibitor with an IC50 value of 40 nM.

Myristoylated Autocamtide-2-related inhibitory peptide, trifluoroacetic acid (TFA) form, is a potent and highly specific inhibitor of CaMKII, exhibiting an IC50 of 40 nM [1]. This compound constitutes the myristoylated variant of Autocamtide-2-related inhibitory peptide.

IKKγ NBD Inhibitory Peptide TFA is a specific NF-κB inhibitor that hinders the interaction between the IKKγ NEMO-binding domain (NBD) and IKKα and IKKβ, effectively preventing TNF-α-induced NF-κB activation. It has been demonstrated to significantly suppress inflammation and improve neurological deficits induced by cerebral ischemia [1] [2] [3].

Glucagon-like peptide 1 (1-37), human (TFA), is a highly potent agonist of the GLP-1 receptor and is a pancreatic hormone synthesized through post-translational processing of proglucagon.

AMARA peptide (TFA) serves as a substrate for both salt-inducible kinase (SIK) and adenosine monophosphate-activated protein kinase (AMPK).

Sakamototide substrate peptide TFA is a peptide substrate of the AMPK kinase family, used to determine kinase activity.

EGFR peptide (myristoylated), a synthetic peptide inhibitor of PKC (IC50 = 5 µM), corresponds to the intracellular region's amino acid sequence of EGFR. It effectively reverses doxorubicin resistance in UV-2237M (UV-2237M-ADRR) fibrosarcoma cells at a concentration of 1 µM.

Bim BH3, Peptide IV TFA is a 26-site residue of BH3 protein Bim, belonging to the pro-apoptotic group of bcl-2 protein family.

Ptd-p65-p1 Peptide TFA is a nuclear transcription factor nf-kappab inhibitor, consisting of a membrane transport Peptide sequence derived from antennapedia linked to p65-p1, selectively inhibiting nf-kappab activity induced by various stimuli.

RGD peptide (GRGDNP) TFA functions as an inhibitor of integrin-ligand interactions, competitively blocking α5β1's interaction with the extracellular matrix (ECM). It induces apoptosis by triggering conformational changes that facilitate pro-caspase-3 activation and autoprocessing. Furthermore, RGD peptide (GRGDNP) TFA is critical in regulating cell adhesion, migration, growth, and differentiation [1] [2] [3].

Bim BH3, Peptide IV TFA, is a 26-residue peptide derived from the BH3-only protein Bim, a member of the pro-apoptotic Bcl-2 protein family [1] [2].

Calcineurin Autoinhibitory Peptide TFA is a selective inhibitor of Ca2+/calmodulin-dependent protein phosphatase (calcineurin), exhibiting an inhibitory concentration (IC50) of approximately 10 μM. This compound has been shown to protect neurons from excitatory neuronal death [1] [2].

Calcitonin Gene-Related Peptide (CGRP) II, rat TFA, functions as a potent and enduring vasodilator by activating CGRP receptors. This compound is utilized in cardiovascular disease research [1].

Peptide YY (PYY) (3-36), porcine TFA, acts as a gut hormone and Y2 receptor agonist, effectively reducing appetite [1].

Akt SKG Substrate Peptide TFA is a synthetic peptide specifically designed as a substrate for Akt PKB and is not phosphorylated by p70S6K or MAPK1 [1].

α2β1 Integrin Ligand Peptide TFA interacts with integrin receptors on the cell membrane, mediating extracellular signaling and potentially acting as an antagonist of the collagen receptor.

Vasonatrin Peptide (VNP) TFA, a chimeric compound derived from atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP), exhibits venodilating properties reminiscent of CNP, natriuretic effects akin to ANP, as well as unique arterial vasodilating capabilities not characteristic of either parent peptide. Additionally, VNP TFA confers cardioprotection in diabetic ischemia-reperfusion injury by attenuating endoplasmic reticulum (ER) stress through the cGMP-PKG signaling cascade [1] [2] [3].

Acetyl Gastric Inhibitory Peptide (human) TFA, a fatty acid-derivatized analog of the glucose-dependent insulinotropic polypeptide, exhibits enhanced antihyperglycemic and insulinotropic properties. It is utilized in the research of diabetes, insulin resistance, and obesity [1] [2] [3].

Gastric inhibitory peptide (GIP) (1-42), an endogenous incretin hormone comprising 42 amino acids, promotes insulin secretion. Expressed in the intestinal neuroendocrine K cells and submandibular gland, it enters circulation after meals. GIP (1-42) blocks histamine, pentagastrin, and insulin-induced gastric acid and pepsin secretion, enhances glucose-stimulated insulin release, and accelerates gastric emptying in rats.

EGFRvIII peptide, a synthetic peptide mirroring the EGFRvIII fusion junction—a tumor-specific, perpetually active EGFR variant missing amino acids 6-273 of the wild-type—binds to HLA-A*0201-positive T2 cells under MHC class I at 25 µg/ml. It enables antigen presentation in dendritic cells from human peripheral blood mononuclear cells (PBMCs), thus activating CD8+ cytotoxic T lymphocytes and prompting IFN-γ production. Administered at 15 µg/animal with the TLR5 agonist flagellin B, EGFRvIII peptide elevates CD8+ T cell numbers, lowers regulatory T cells (Tregs) in the brain, diminishes tumor volume, and extends survival in a GL261 glioblastoma mouse model.

AMARA peptide (TFA) is a substrate for salt-induced kinase (SIK) and adenosine activated protein kinase (AMPK).

RGD peptide (GRGDNP) (TFA) promote apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing.

PAR-4 Agonist Peptide, amide TFA (PAR-4-AP (TFA)), is a selective activator of the proteinase-activated receptor-4 (PAR-4) that does not affect PAR-1 or PAR-2, and its activity can be inhibited by a PAR-4 antagonist.

Lyn Peptide Inhibitor TFA is a powerful, cell-permeable inhibitor specifically targeting the Lyn-coupled IL-5 receptor signaling pathway, without affecting alternative signaling pathways. It effectively prevents Lyn activation and impedes the association between Lyn tyrosine kinase and the βc subunit of IL-3/GM-CSF/IL-5 receptors. This compound is utilized in the investigation of asthma, allergic reactions, and various eosinophilic conditions [1].

Phospho-Glycogen Synthase Peptide-2 (substrate) serves as a peptide substrate for glycogen synthase kinase-3 (GSK-3) and is used for the affinity purification of protein-serine kinases [1].

iRGD Peptide 1 TFA is a prototypic tumor-homing peptide with tissue-penetrating capabilities, facilitating deep delivery of therapeutic agents into extravascular tumor tissue. Additionally, it possesses anti-metastatic activity [1].

Brain Natriuretic Peptide-45, rat TFA (BNP-45, rat TFA) is an isoform of the rat brain natriuretic peptide extracted from the rat heart, exhibiting significant hypotensive and natriuretic effects [1].

PDZ1 Domain Inhibitor Peptide TFA, a cyclic peptide featuring a β-Ala lactam side chain linker, specifically targets the PDZ1 domains of postsynaptic density protein 95 (PSD-95). It effectively disrupts the GluR6/PSD-95 interaction, competing against the C terminus of GluR6 for the PDZ1 domain with high efficiency [1].

Klotho-derived peptide 1 (KP1) (56-87), a peptide originating from the human Klotho protein, disrupts TGF-β signaling by binding to TGF-β receptor types 1 and 2 (TGFBR1 and TGFBR2; Kds = 1.41 and 14.6 µM, respectively). Preincubation with KP1 at a concentration of 10 µg/ml hinders the TGF-β-induced escalation of fibronectin and α-smooth muscle actin (α-SMA) levels in NRK-49F rat fibroblasts. Furthermore, in vivo studies reveal that KP1, administered at 1 mg/kg per day, preferentially accumulates in damaged kidneys, leading to significant reductions in serum creatinine and blood urea nitrogen levels, indicators of improved kidney function. Additionally, it decreases kidney fibrosis in mouse models of unilateral ureteral obstruction (UUO) and unilateral ischemia-reperfusion injury-induced renal fibrosis.

OVA-E1 peptide TFA activates the p38 and JNK cascades similarly in mutant and wild-type thymocytes.

Peptide YY (PYY) (3-36), human (TFA) is a gut hormone peptide that acts as a Y2 receptor agonist to reduce appetite[1].

Gastric inhibitory peptide (GIP) (22-51), a pro-atherogenic peptide comprised of 30 amino acids from the residues 22-51 of its precursor protein proGIP, is present in human plasma. It activates the degradation of IκB-α and the nuclear translocation of NF-κB in both macrophage-differentiated THP-1 cells and human aortic endothelial cells at a concentration of 1 µM. Additionally, in ApoE-/- mice, GIP (22-51) escalates the area of atherosclerotic lesions and plaque development in vivo.

SLLK, Control Peptide for TSP1 Inhibitor (TFA) is a control peptide for LSKL, which is a Thrombospondin (TSP-1) inhibitor.

Protein Kinase C (alpha) Peptide (TFA) is a PKC-α-associated peptide functioning as a lipid-dependent serine/threonine protein kinase. It plays a pivotal role in regulating several cellular functions such as survival, proliferation, differentiation, migration, and adhesion [1].

Peptide T (TFA), an octapeptide derived from the V2 region of HIV-1 gp120, functions as a ligand for the CD4 receptor, thereby effectively inhibiting HIV binding to the CD4 receptor.